{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T20:19:13Z","timestamp":1781209153297,"version":"3.54.1"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T00:00:00Z","timestamp":1768953600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"vor","delay-in-days":26,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Medical Science and Technology Program of Henan Province","award":["SBGJ 202302047"],"award-info":[{"award-number":["SBGJ 202302047"]}]},{"name":"Medical Science and Technology Program of Henan Province","award":["SBGJ 202302069"],"award-info":[{"award-number":["SBGJ 202302069"]}]},{"DOI":"10.13039\/501100001809","name":"The National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82000826"],"award-info":[{"award-number":["82000826"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Commun Signal"],"DOI":"10.1186\/s12964-026-02668-8","type":"journal-article","created":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T03:35:18Z","timestamp":1768966518000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Identification of the E3 ligase TRIM21 as a crucial regulator of STAT1 in metabolic dysfunction\u2014associated steatohepatitis"],"prefix":"10.1186","volume":"24","author":[{"given":"Xun-Xun","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-Ting","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Li","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin-Bin","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dian-Hong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei-Ming","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Na","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie-Lei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,21]]},"reference":[{"key":"2668_CR1","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1097\/CM9.0000000000002277","volume":"135","author":"J Liu","year":"2022","unstructured":"Liu J, et al. Estimating global prevalence, incidence, and outcomes of non-alcoholic fatty liver disease from 2000 to 2021: systematic review and meta-analysis. Chin Med J (Engl). 2022;135:1682\u201391. https:\/\/doi.org\/10.1097\/CM9.0000000000002277.","journal-title":"Chin Med J (Engl)"},{"key":"2668_CR2","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","volume":"64","author":"ZM Younossi","year":"2016","unstructured":"Younossi ZM, et al. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64:73\u201384. https:\/\/doi.org\/10.1002\/hep.28431.","journal-title":"Hepatology"},{"key":"2668_CR3","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/med.21515","volume":"39","author":"J Cai","year":"2019","unstructured":"Cai J, Zhang X-J, Li H. Progress and challenges in the prevention and control of nonalcoholic fatty liver disease. Med Res Rev. 2019;39:328\u201348. https:\/\/doi.org\/10.1002\/med.21515.","journal-title":"Med Res Rev"},{"key":"2668_CR4","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1002\/hep.31150","volume":"71","author":"J Zhou","year":"2020","unstructured":"Zhou J, et al. Epidemiological features of NAFLD from 1999 to 2018 in China. Hepatology. 2020;71:1851\u201364. https:\/\/doi.org\/10.1002\/hep.31150.","journal-title":"Hepatology"},{"key":"2668_CR5","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","volume":"15","author":"Z Younossi","year":"2018","unstructured":"Younossi Z, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15:11\u201320. https:\/\/doi.org\/10.1038\/nrgastro.2017.109.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2668_CR6","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1038\/s41591-023-02242-6","volume":"29","author":"SA Harrison","year":"2023","unstructured":"Harrison SA, Allen AM, Dubourg J, Noureddin M, Alkhouri N. Challenges and opportunities in NASH drug development. Nat Med. 2023;29:562\u201373. https:\/\/doi.org\/10.1038\/s41591-023-02242-6.","journal-title":"Nat Med"},{"key":"2668_CR7","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","volume":"24","author":"SL Friedman","year":"2018","unstructured":"Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ. Mechanisms of NAFLD development and therapeutic strategies. Nat Med. 2018;24:908\u201322. https:\/\/doi.org\/10.1038\/s41591-018-0104-9.","journal-title":"Nat Med"},{"key":"2668_CR8","doi-asserted-by":"publisher","first-page":"S47","DOI":"10.1016\/j.jhep.2014.12.012","volume":"62","author":"CD Byrne","year":"2015","unstructured":"Byrne CD, Targher G. NAFLD: A multisystem disease. J Hepatol. 2015;62:S47\u201364. https:\/\/doi.org\/10.1016\/j.jhep.2014.12.012.","journal-title":"J Hepatol"},{"key":"2668_CR9","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1016\/j.metabol.2015.05.002","volume":"64","author":"SH Ganji","year":"2015","unstructured":"Ganji SH, Kashyap ML, Kamanna VSN. Niacin inhibits fat accumulation, oxidative stress, and inflammatory cytokine IL-8 in cultured hepatocytes: impact on non-alcoholic fatty liver disease. Metabolism. 2015;64:982\u201390. https:\/\/doi.org\/10.1016\/j.metabol.2015.05.002.","journal-title":"Metabolism"},{"key":"2668_CR10","doi-asserted-by":"publisher","first-page":"530","DOI":"10.4254\/wjh.v10.i8.530","volume":"10","author":"Q Li","year":"2018","unstructured":"Li Q, Dhyani M, Grajo JR, Sirlin C, Samir AE. Current status of imaging in nonalcoholic fatty liver disease. World J Hepatol. 2018;10:530\u201342. https:\/\/doi.org\/10.4254\/wjh.v10.i8.530.","journal-title":"World J Hepatol"},{"key":"2668_CR11","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1016\/j.metabol.2015.12.012","volume":"65","author":"E Buzzetti","year":"2016","unstructured":"Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism. 2016;65:1038\u201348. https:\/\/doi.org\/10.1016\/j.metabol.2015.12.012.","journal-title":"Metabolism"},{"key":"2668_CR12","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1038\/s41401-021-00849-4","volume":"43","author":"S-Y Tian","year":"2022","unstructured":"Tian S-Y, Chen S-M, Pan C-X, Li Y. FXR: structures, biology, and drug development for NASH and fibrosis diseases. Acta Pharmacol Sin. 2022;43:1120\u201332. https:\/\/doi.org\/10.1038\/s41401-021-00849-4.","journal-title":"Acta Pharmacol Sin"},{"key":"2668_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2021.06.012","author":"BL Clifford","year":"2021","unstructured":"Clifford BL, et al. FXR activation protects against NAFLD via bile-acid-dependent reductions in lipid absorption. Cell Metab. 2021. https:\/\/doi.org\/10.1016\/j.cmet.2021.06.012.","journal-title":"Cell Metab"},{"key":"2668_CR14","doi-asserted-by":"publisher","first-page":"108391","DOI":"10.1016\/j.pharmthera.2023.108391","volume":"245","author":"H Chen","year":"2023","unstructured":"Chen H, et al. PPAR-\u03b3 signaling in nonalcoholic fatty liver disease: pathogenesis and therapeutic targets. Pharmacol Ther. 2023;245:108391. https:\/\/doi.org\/10.1016\/j.pharmthera.2023.108391.","journal-title":"Pharmacol Ther"},{"key":"2668_CR15","doi-asserted-by":"publisher","first-page":"E730","DOI":"10.1152\/ajpendo.00225.2016","volume":"311","author":"BK Smith","year":"2016","unstructured":"Smith BK, et al. Treatment of nonalcoholic fatty liver disease: role of AMPK. Am J Physiol Endocrinol Metab. 2016;311:E730\u201340. https:\/\/doi.org\/10.1152\/ajpendo.00225.2016.","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2668_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/molecules27134275","author":"L Tao","year":"2022","unstructured":"Tao L, Ren X, Zhai W, Chen Z. Progress and prospects of non-canonical NF-\u03baB signaling pathway in the regulation of liver diseases. Molecules. 2022. https:\/\/doi.org\/10.3390\/molecules27134275.","journal-title":"Molecules"},{"key":"2668_CR17","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.3389\/fphar.2018.01428","volume":"9","author":"D Xu","year":"2018","unstructured":"Xu D, et al. The role of Nrf2 in liver disease: novel molecular mechanisms and therapeutic approaches. Front Pharmacol. 2018;9:1428. https:\/\/doi.org\/10.3389\/fphar.2018.01428.","journal-title":"Front Pharmacol"},{"key":"2668_CR18","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.molmet.2016.12.001","volume":"6","author":"G Solinas","year":"2017","unstructured":"Solinas G, Becattini B. JNK at the crossroad of obesity, insulin resistance, and cell stress response. Mol Metab. 2017;6:174\u201384. https:\/\/doi.org\/10.1016\/j.molmet.2016.12.001.","journal-title":"Mol Metab"},{"key":"2668_CR19","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1053\/jhep.2001.28054","volume":"34","author":"SQ Yang","year":"2001","unstructured":"Yang SQ, Lin HZ, Mandal AK, Huang J, Diehl AM. Disrupted signaling and inhibited regeneration in obese mice with fatty livers: implications for nonalcoholic fatty liver disease pathophysiology. Hepatology. 2001;34:694\u2013706.","journal-title":"Hepatology"},{"key":"2668_CR20","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1136\/gutjnl-2019-318372","volume":"69","author":"A Mart\u00ed-Rodrigo","year":"2020","unstructured":"Mart\u00ed-Rodrigo A, et al. Rilpivirine attenuates liver fibrosis through selective STAT1-mediated apoptosis in hepatic stellate cells. Gut. 2020;69:920\u201332. https:\/\/doi.org\/10.1136\/gutjnl-2019-318372.","journal-title":"Gut"},{"key":"2668_CR21","doi-asserted-by":"publisher","first-page":"2062","DOI":"10.1182\/blood-2007-05-091207","volume":"111","author":"A Chaudhuri","year":"2008","unstructured":"Chaudhuri A, Yang B, Gendelman HE, Persidsky Y, Kanmogne GD. STAT1 signaling modulates HIV-1-induced inflammatory responses and leukocyte transmigration across the blood-brain barrier. Blood. 2008;111:2062\u201372. https:\/\/doi.org\/10.1182\/blood-2007-05-091207.","journal-title":"Blood"},{"key":"2668_CR22","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1016\/j.cell.2018.09.053","volume":"175","author":"M Grohmann","year":"2018","unstructured":"Grohmann M, et al. Obesity Drives STAT-1-Dependent NASH and STAT-3-Dependent HCC. Cell. 2018;175:1289-1306.e1220. https:\/\/doi.org\/10.1016\/j.cell.2018.09.053.","journal-title":"Cell"},{"key":"2668_CR23","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.molimm.2021.03.005","volume":"134","author":"J Li","year":"2021","unstructured":"Li J, et al. IFN-\u03b3 contributes to the hepatic inflammation in HFD-induced nonalcoholic steatohepatitis by STAT1\u03b2\/TLR2 signaling pathway. Mol Immunol. 2021;134:118\u201328. https:\/\/doi.org\/10.1016\/j.molimm.2021.03.005.","journal-title":"Mol Immunol"},{"key":"2668_CR24","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1021\/acs.jafc.0c06652","volume":"69","author":"N Luo","year":"2021","unstructured":"Luo N, Yang C, Zhu Y, Chen Q, Zhang B. Diosmetin ameliorates nonalcoholic steatohepatitis through modulating lipogenesis and inflammatory response in a STAT1\/CXCL10-dependent manner. J Agric Food Chem. 2021;69:655\u201367. https:\/\/doi.org\/10.1021\/acs.jafc.0c06652.","journal-title":"J Agric Food Chem"},{"key":"2668_CR25","doi-asserted-by":"publisher","first-page":"119358","DOI":"10.1016\/j.jep.2025.119358","volume":"341","author":"P Li","year":"2025","unstructured":"Li P, Zhang R, Hu P, Wang T, Wang J. Cepharanthine relieves nonalcoholic steatohepatitis through inhibiting STAT1\/CXCL10 axis-mediated lipogenesis and inflammatory responses. J Ethnopharmacol. 2025;341:119358. https:\/\/doi.org\/10.1016\/j.jep.2025.119358.","journal-title":"J Ethnopharmacol"},{"key":"2668_CR26","doi-asserted-by":"publisher","first-page":"5927","DOI":"10.1038\/s41467-025-61028-1","volume":"16","author":"J Han","year":"2025","unstructured":"Han J, et al. Cardiomyocyte-derived USP13 protects hearts from hypertrophy via deubiquitinating and stabilizing STAT1 in male mice. Nat Commun. 2025;16:5927. https:\/\/doi.org\/10.1038\/s41467-025-61028-1.","journal-title":"Nat Commun"},{"key":"2668_CR27","doi-asserted-by":"publisher","first-page":"17006","DOI":"10.1074\/jbc.M112.341198","volume":"287","author":"C Yuan","year":"2012","unstructured":"Yuan C, Qi J, Zhao X, Gao C. Smurf1 protein negatively regulates interferon-\u03b3 signaling through promoting STAT1 protein ubiquitination and degradation. J Biol Chem. 2012;287:17006\u201315. https:\/\/doi.org\/10.1074\/jbc.M112.341198.","journal-title":"J Biol Chem"},{"key":"2668_CR28","doi-asserted-by":"publisher","first-page":"e1005764","DOI":"10.1371\/journal.ppat.1005764","volume":"12","author":"Y Ren","year":"2016","unstructured":"Ren Y, et al. Deubiquitinase USP2a sustains interferons antiviral activity by restricting ubiquitination of activated STAT1 in the nucleus. PLoS Pathog. 2016;12:e1005764. https:\/\/doi.org\/10.1371\/journal.ppat.1005764.","journal-title":"PLoS Pathog"},{"key":"2668_CR29","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1038\/s41418-020-00609-7","volume":"28","author":"X Guo","year":"2021","unstructured":"Guo X, et al. Rnf220 mediates K63-linked polyubiquitination of STAT1 and promotes host defense. Cell Death Differ. 2021;28:640\u201356. https:\/\/doi.org\/10.1038\/s41418-020-00609-7.","journal-title":"Cell Death Differ"},{"key":"2668_CR30","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.tibs.2017.01.002","volume":"42","author":"S Hatakeyama","year":"2017","unstructured":"Hatakeyama S. Trim family proteins: roles in autophagy, immunity, and carcinogenesis. Trends Biochem Sci. 2017;42:297\u2013311. https:\/\/doi.org\/10.1016\/j.tibs.2017.01.002.","journal-title":"Trends Biochem Sci"},{"key":"2668_CR31","doi-asserted-by":"publisher","first-page":"3687","DOI":"10.2147\/CMAR.S175470","volume":"10","author":"W Zhou","year":"2018","unstructured":"Zhou W, et al. Decreased expression of TRIM21 indicates unfavorable outcome and promotes cell growth in breast cancer. Cancer Manag Res. 2018;10:3687\u201396. https:\/\/doi.org\/10.2147\/CMAR.S175470.","journal-title":"Cancer Manag Res"},{"key":"2668_CR32","doi-asserted-by":"publisher","first-page":"105576","DOI":"10.1016\/j.oraloncology.2021.105576","volume":"122","author":"Y Zhao","year":"2021","unstructured":"Zhao Y, et al. WIPI-1 inhibits metastasis and tumour growth via the WIPI-1-TRIM21 axis and MYC regulation in nasopharyngeal carcinoma. Oral Oncol. 2021;122:105576. https:\/\/doi.org\/10.1016\/j.oraloncology.2021.105576.","journal-title":"Oral Oncol"},{"key":"2668_CR33","doi-asserted-by":"publisher","DOI":"10.26508\/lsa.202302060","author":"Y Xu","year":"2023","unstructured":"Xu Y, et al. Regulation of hPCL3 isoforms\u2019 ubiquitination by TRIM21 in non-small cell lung cancer progression. Life Sci Alliance. 2023. https:\/\/doi.org\/10.26508\/lsa.202302060.","journal-title":"Life Sci Alliance"},{"key":"2668_CR34","doi-asserted-by":"publisher","first-page":"738473","DOI":"10.3389\/fimmu.2021.738473","volume":"12","author":"EL Jones","year":"2021","unstructured":"Jones EL, Laidlaw SM, Dustin LB. TRIM21\/Ro52 - roles in innate immunity and autoimmune disease. Front Immunol. 2021;12:738473. https:\/\/doi.org\/10.3389\/fimmu.2021.738473.","journal-title":"Front Immunol"},{"key":"2668_CR35","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1186\/s12935-023-03143-x","volume":"23","author":"C-H Hsu","year":"2023","unstructured":"Hsu C-H, Yu Y-L. The interconnected roles of TRIM21\/Ro52 in systemic lupus erythematosus, primary Sj\u00f6gren\u2019s syndrome, cancers, and cancer metabolism. Cancer Cell Int. 2023;23:289. https:\/\/doi.org\/10.1186\/s12935-023-03143-x.","journal-title":"Cancer Cell Int"},{"key":"2668_CR36","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.jaut.2012.01.014","volume":"39","author":"V Oke","year":"2012","unstructured":"Oke V, Wahren-Herlenius M. The immunobiology of Ro52 (TRIM21) in autoimmunity: a critical review. J Autoimmun. 2012;39:77\u201382. https:\/\/doi.org\/10.1016\/j.jaut.2012.01.014.","journal-title":"J Autoimmun"},{"key":"2668_CR37","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1016\/j.jcmgh.2021.01.007","volume":"11","author":"F Wang","year":"2021","unstructured":"Wang F, et al. The ubiquitin E3 ligase TRIM21 promotes hepatocarcinogenesis by suppressing the p62-Keap1-Nrf2 antioxidant pathway. Cell Mol Gastroenterol Hepatol. 2021;11:1369\u201385. https:\/\/doi.org\/10.1016\/j.jcmgh.2021.01.007.","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"2668_CR38","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1007\/s00018-023-04820-w","volume":"80","author":"K Zhang","year":"2023","unstructured":"Zhang K, et al. TRIM21 ameliorates hepatic glucose and lipid metabolic disorders in type 2 diabetes mellitus by ubiquitination of PEPCK1 and FASN. Cell Mol Life Sci. 2023;80:168. https:\/\/doi.org\/10.1007\/s00018-023-04820-w.","journal-title":"Cell Mol Life Sci"},{"key":"2668_CR39","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1038\/s41422-020-00443-z","volume":"31","author":"P Xie","year":"2021","unstructured":"Xie P, et al. Neddylation of PTEN regulates its nuclear import and promotes tumor development. Cell Res. 2021;31:291\u2013311. https:\/\/doi.org\/10.1038\/s41422-020-00443-z.","journal-title":"Cell Res"},{"key":"2668_CR40","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.164694","author":"KC Nikolaou","year":"2023","unstructured":"Nikolaou KC, et al. Inflammation-induced TRIM21 represses hepatic steatosis by promoting the ubiquitination of lipogenic regulators. JCI Insight. 2023. https:\/\/doi.org\/10.1172\/jci.insight.164694.","journal-title":"JCI Insight"},{"key":"2668_CR41","doi-asserted-by":"publisher","unstructured":"F Xie et al 2025 Macrophage TRIM21 knockout inhibits septic acute lung injury by downregulating autophagy regulator protein ubiquitination Autophagy 12 https:\/\/doi.org\/10.1080\/15548627.2025.2519063","DOI":"10.1080\/15548627.2025.2519063"},{"key":"2668_CR42","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1038\/s41419-023-06383-x","volume":"14","author":"R Zhang","year":"2023","unstructured":"Zhang R, et al. TRIM21-mediated Sohlh2 ubiquitination suppresses M2 macrophage polarization and progression of triple-negative breast cancer. Cell Death Dis. 2023;14:850. https:\/\/doi.org\/10.1038\/s41419-023-06383-x.","journal-title":"Cell Death Dis"},{"key":"2668_CR43","doi-asserted-by":"publisher","first-page":"e54391","DOI":"10.15252\/embr.202154391","volume":"23","author":"P Yao","year":"2022","unstructured":"Yao P, Chen T, Jiang P, Li L, Du W. Functional skewing of TRIM21-SIRT5 interplay dictates IL-1\u03b2 production in DSS-induced colitis. EMBO Rep. 2022;23:e54391. https:\/\/doi.org\/10.15252\/embr.202154391.","journal-title":"EMBO Rep"},{"key":"2668_CR44","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1016\/j.cmet.2023.05.011","volume":"35","author":"X Lu","year":"2023","unstructured":"Lu X, et al. UBE2M-mediated neddylation of TRIM21 regulates obesity-induced inflammation and metabolic disorders. Cell Metab. 2023;35:1390-1405.e1398. https:\/\/doi.org\/10.1016\/j.cmet.2023.05.011.","journal-title":"Cell Metab"},{"key":"2668_CR45","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s43556-022-00089-w","volume":"3","author":"Y Dong","year":"2022","unstructured":"Dong Y, et al. MicroRNA-379-5p regulates free cholesterol accumulation and relieves diet induced-liver damage in db\/db mice via STAT1\/HMGCS1 axis. Mol Biomed. 2022;3:25. https:\/\/doi.org\/10.1186\/s43556-022-00089-w.","journal-title":"Mol Biomed"},{"key":"2668_CR46","doi-asserted-by":"publisher","first-page":"101789","DOI":"10.1016\/j.molmet.2023.101789","volume":"76","author":"Z Bai","year":"2023","unstructured":"Bai Z, et al. Prdx1 Cys52Ser variant alleviates nonalcoholic steatohepatitis by reducing inflammation in mice. Mol Metab. 2023;76:101789. https:\/\/doi.org\/10.1016\/j.molmet.2023.101789.","journal-title":"Mol Metab"},{"key":"2668_CR47","doi-asserted-by":"publisher","first-page":"3249","DOI":"10.1002\/jcb.25973","volume":"118","author":"K Tomita","year":"2017","unstructured":"Tomita K, et al. Mixed lineage kinase 3 mediates the induction of CXCL10 by a STAT1-dependent mechanism during hepatocyte lipotoxicity. J Cell Biochem. 2017;118:3249\u201359. https:\/\/doi.org\/10.1002\/jcb.25973.","journal-title":"J Cell Biochem"},{"key":"2668_CR48","doi-asserted-by":"publisher","first-page":"102679","DOI":"10.1016\/j.redox.2023.102679","volume":"62","author":"X Liu","year":"2023","unstructured":"Liu X, et al. TRIM21 deficiency protects against atrial inflammation and remodeling post myocardial infarction by attenuating oxidative stress. Redox Biol. 2023;62:102679. https:\/\/doi.org\/10.1016\/j.redox.2023.102679.","journal-title":"Redox Biol"},{"key":"2668_CR49","doi-asserted-by":"publisher","first-page":"4919","DOI":"10.7150\/thno.85662","volume":"13","author":"Y Li","year":"2023","unstructured":"Li Y, et al. E3 ubiquitin ligase TRIM21 targets TIF1\u03b3 to regulate \u03b2-catenin signaling in glioblastoma. Theranostics. 2023;13:4919\u201335. https:\/\/doi.org\/10.7150\/thno.85662.","journal-title":"Theranostics"},{"key":"2668_CR50","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1038\/s41418-021-00867-z","volume":"29","author":"W Gao","year":"2022","unstructured":"Gao W, et al. TRIM21 regulates pyroptotic cell death by promoting Gasdermin D oligomerization. Cell Death Differ. 2022;29:439\u201350. https:\/\/doi.org\/10.1038\/s41418-021-00867-z.","journal-title":"Cell Death Differ"},{"key":"2668_CR51","doi-asserted-by":"publisher","first-page":"114095","DOI":"10.1016\/j.celrep.2024.114095","volume":"43","author":"YY Guo","year":"2024","unstructured":"Guo YY, et al. Viral infection and spread are inhibited by the polyubiquitination and downregulation of TRPV2 channel by the interferon-stimulated gene TRIM21. Cell Rep. 2024;43:114095. https:\/\/doi.org\/10.1016\/j.celrep.2024.114095.","journal-title":"Cell Rep"},{"key":"2668_CR52","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1038\/s41467-023-36523-y","volume":"14","author":"JY Li","year":"2023","unstructured":"Li JY, et al. TRIM21 inhibits irradiation-induced mitochondrial DNA release and impairs antitumour immunity in nasopharyngeal carcinoma tumour models. Nat Commun. 2023;14:865. https:\/\/doi.org\/10.1038\/s41467-023-36523-y.","journal-title":"Nat Commun"},{"key":"2668_CR53","doi-asserted-by":"publisher","first-page":"1880","DOI":"10.1038\/s41467-020-15819-3","volume":"11","author":"J Cheng","year":"2020","unstructured":"Cheng J, et al. TRIM21 and PHLDA3 negatively regulate the crosstalk between the PI3K\/AKT pathway and PPP metabolism. Nat Commun. 2020;11:1880. https:\/\/doi.org\/10.1038\/s41467-020-15819-3.","journal-title":"Nat Commun"},{"key":"2668_CR54","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1126\/science.abn1366","volume":"379","author":"AS Mukadam","year":"2023","unstructured":"Mukadam AS, et al. Cytosolic antibody receptor TRIM21 is required for effective tau immunotherapy in mouse models. Science. 2023;379:1336\u201341. https:\/\/doi.org\/10.1126\/science.abn1366.","journal-title":"Science"},{"key":"2668_CR55","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1126\/science.adp5186","volume":"385","author":"J Benn","year":"2024","unstructured":"Benn J, et al. Aggregate-selective removal of pathological tau by clustering-activated degraders. Science (New York, NY). 2024;385:1009\u201316. https:\/\/doi.org\/10.1126\/science.adp5186.","journal-title":"Science (New York, NY)"}],"container-title":["Cell Communication and Signaling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12964-026-02668-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-026-02668-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-026-02668-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:02:14Z","timestamp":1771286534000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12964-026-02668-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,21]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2668"],"URL":"https:\/\/doi.org\/10.1186\/s12964-026-02668-8","relation":{},"ISSN":["1478-811X"],"issn-type":[{"value":"1478-811X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,21]]},"assertion":[{"value":"1 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"116"}}